- Home
- EXEL vs EVGOW Comparison
EXEL vs EVGOW Comparison
Compare EXEL & EVGOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- EVGOW
- Stock Information
- Founded
- EXEL 1994
- EVGOW 2010
- Country
- EXEL United States
- EVGOW United States
- Employees
- EXEL N/A
- EVGOW 331
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- EVGOW Other Specialty Stores
- Sector
- EXEL Health Care
- EVGOW Consumer Discretionary
- Exchange
- EXEL Nasdaq
- EVGOW Nasdaq
- Market Cap
- EXEL 9.8B
- EVGOW N/A
- IPO Year
- EXEL 2000
- EVGOW N/A
- Fundamental
- Price
- EXEL $36.17
- EVGOW $0.27
- Analyst Decision
- EXEL Buy
- EVGOW
- Analyst Count
- EXEL 18
- EVGOW 0
- Target Price
- EXEL $37.59
- EVGOW N/A
- AVG Volume (30 Days)
- EXEL 2.2M
- EVGOW 74.7K
- Earning Date
- EXEL 05-13-2025
- EVGOW 03-07-2025
- Dividend Yield
- EXEL N/A
- EVGOW N/A
- EPS Growth
- EXEL 170.77
- EVGOW N/A
- EPS
- EXEL 1.76
- EVGOW N/A
- Revenue
- EXEL $2,168,701,000.00
- EVGOW $239,306,000.00
- Revenue This Year
- EXEL $5.78
- EVGOW N/A
- Revenue Next Year
- EXEL $10.94
- EVGOW N/A
- P/E Ratio
- EXEL $20.64
- EVGOW N/A
- Revenue Growth
- EXEL 18.50
- EVGOW 73.08
- 52 Week Low
- EXEL $20.14
- EVGOW $0.12
- 52 Week High
- EXEL $40.26
- EVGOW $1.99
- Technical
- Relative Strength Index (RSI)
- EXEL 43.89
- EVGOW 59.34
- Support Level
- EXEL $34.90
- EVGOW $0.18
- Resistance Level
- EXEL $40.26
- EVGOW $0.38
- Average True Range (ATR)
- EXEL 1.21
- EVGOW 0.05
- MACD
- EXEL -0.19
- EVGOW 0.01
- Stochastic Oscillator
- EXEL 23.69
- EVGOW 51.85
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About EVGOW EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.